Alessandro Mussa1, Cristina Molinatto2, Giuseppina Baldassarre2, Evelise Riberi2, Silvia Russo3, Lidia Larizza3, Andrea Riccio4, Giovanni Battista Ferrero2. 1. Department of Pediatric and Public Health Sciences, University of Torino, Torino, Italy. Electronic address: alessandro.mussa@unito.it. 2. Department of Pediatric and Public Health Sciences, University of Torino, Torino, Italy. 3. Laboratory of Cytogenetics and Molecular Genetics, Istituto Auxologico Italiano, Milan, Italy. 4. Department of Environmental, Biological and Pharmaceutical Sciences, Second University of Naples and Institute of Genetics and Biophysics "A. Buzzati-Traverso", CNR, Naples, Italy.
Abstract
OBJECTIVE: To compare tumor risk in the 4 Beckwith-Wiedemann syndrome (BWS) molecular subgroups: Imprinting Control Region 1 Gain of Methylation (ICR1-GoM), Imprinting Control Region 2 Loss of Methylation (ICR2-LoM), Chromosome 11p15 Paternal Uniparental Disomy (UPD), and Cyclin-Dependent Kinase Inhibitor 1C gene (CDKN1C) mutation. STUDY DESIGN: Studies on BWS and tumor development published between 2000 and 2015 providing (epi)genotype-cancer correlations with histotype data were reviewed and meta-analysed with cancer histotypes as measured outcome and (epi)genotype as exposure. RESULTS: A total of 1370 patients with BWS were included: 102 developed neoplasms (7.4%). Tumor prevalence was 2.5% in ICR2-LoM, 13.8% in UPD, 22.8% in ICR1-GoM, and 8.6% in patients with CDKN1C mutations. Cancer ORs were 12.8 in ICR1-GoM, 6.5 in UPD, and 2.9 in patients with CDKN1C mutations compared with patients with ICR2-LoM. Wilms tumor was associated with ICR1-GoM (OR 68.3) and UPD (OR 13.2). UPD also was associated with hepatoblastoma (OR 5.2) and adrenal carcinoma (OR 7.0), and CDKN1C mutations with neuroblastic tumors (OR 7.2). CONCLUSION: Cancer screening in BWS could be differentiated on the basis of (epi)genotype and target specific histotypes. Patients with ICR1-GoM and UPD should undergo renal ultrasonography scanning, given their risk of Wilms tumor. Alpha feto protein monitoring for heptaoblastoma is suggested in patients with UPD. Adrenal carcinoma may deserve screening in patients with UPD. Patients with CDKN1C mutations may deserve neuroblastoma screening based on urinary markers and ultrasonography scanning. Finally, screening appears questionable in cases of ICR2-LoM, given low tumor risk.
OBJECTIVE: To compare tumor risk in the 4 Beckwith-Wiedemann syndrome (BWS) molecular subgroups: Imprinting Control Region 1 Gain of Methylation (ICR1-GoM), Imprinting Control Region 2 Loss of Methylation (ICR2-LoM), Chromosome 11p15 Paternal Uniparental Disomy (UPD), and Cyclin-Dependent Kinase Inhibitor 1C gene (CDKN1C) mutation. STUDY DESIGN: Studies on BWS and tumor development published between 2000 and 2015 providing (epi)genotype-cancer correlations with histotype data were reviewed and meta-analysed with cancer histotypes as measured outcome and (epi)genotype as exposure. RESULTS: A total of 1370 patients with BWS were included: 102 developed neoplasms (7.4%). Tumor prevalence was 2.5% in ICR2-LoM, 13.8% in UPD, 22.8% in ICR1-GoM, and 8.6% in patients with CDKN1C mutations. Cancer ORs were 12.8 in ICR1-GoM, 6.5 in UPD, and 2.9 in patients with CDKN1C mutations compared with patients with ICR2-LoM. Wilms tumor was associated with ICR1-GoM (OR 68.3) and UPD (OR 13.2). UPD also was associated with hepatoblastoma (OR 5.2) and adrenal carcinoma (OR 7.0), and CDKN1C mutations with neuroblastic tumors (OR 7.2). CONCLUSION:Cancer screening in BWS could be differentiated on the basis of (epi)genotype and target specific histotypes. Patients with ICR1-GoM and UPD should undergo renal ultrasonography scanning, given their risk of Wilms tumor. Alpha feto protein monitoring for heptaoblastoma is suggested in patients with UPD. Adrenal carcinoma may deserve screening in patients with UPD. Patients with CDKN1C mutations may deserve neuroblastoma screening based on urinary markers and ultrasonography scanning. Finally, screening appears questionable in cases of ICR2-LoM, given low tumor risk.
Authors: Suzanne P MacFarland; Sogol Mostoufi-Moab; Kristin Zelley; Peter A Mattei; Lisa J States; Tricia R Bhatti; Kelly A Duffy; Garrett M Brodeur; Jennifer M Kalish Journal: Pediatr Blood Cancer Date: 2017-01-09 Impact factor: 3.167
Authors: Jennifer M Kalish; Leslie G Biesecker; Frederic Brioude; Matthew A Deardorff; Alessandra Di Cesare-Merlone; Todd Druley; Giovanni B Ferrero; Pablo Lapunzina; Lidia Larizza; Saskia Maas; Marina Macchiaiolo; Eamonn R Maher; Silvia Maitz; Julian A Martinez-Agosto; Alessandro Mussa; Peter Robinson; Silvia Russo; Angelo Selicorni; Raoul C Hennekam Journal: Am J Med Genet A Date: 2017-05-05 Impact factor: 2.802
Authors: Alessandro Mussa; Kelly A Duffy; Diana Carli; Giovanni Battista Ferrero; Jennifer M Kalish Journal: Pediatr Blood Cancer Date: 2018-09-30 Impact factor: 3.167